Literature DB >> 12729909

Glutamate substitutions at a PKA consensus site are consistent with inactivation of calpain by phosphorylation.

Scott D Smith1, Zongchao Jia, Kassidy K Huynh, Alan Wells, John S Elce.   

Abstract

Regulation of calpain by phosphorylation has often been suggested, but has proved difficult to detect. Calpains extracted from mammalian tissue are reported to contain 2-4 mol phosphate/mol of enzyme distributed over multiple sites, but phosphate groups are not detectable in the X-ray structures of recombinant calpain. Some serine and threonine residues in the large subunit of rat m-calpain were converted to aspartic or glutamic acid residues, at sites suggested by previous studies, to assess the probable effects of phosphate groups on the enzyme. Expression of the mutant calpains in Escherichia coli, and their heat stabilities, did not differ from those of the wild-type enzyme. m-Calpains with the mutations Ser50Asp, Ser50Glu, Ser67Glu, and Thr70Glu had the same specific activity and Ca(2+) requirement as the wild-type enzyme. In contrast, Ser369Asp-, Ser369Glu-, and Thr370Glu-m-calpain were inactive. This result is consistent with the recent report that phosphorylation at position 369 or 370 in vivo reduced m-calpain activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12729909     DOI: 10.1016/s0014-5793(03)00361-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

1.  m-Calpain activation is regulated by its membrane localization and by its binding to phosphatidylinositol 4,5-bisphosphate.

Authors:  Ludovic Leloup; Hanshuang Shao; Yong Ho Bae; Bridget Deasy; Donna Stolz; Partha Roy; Alan Wells
Journal:  J Biol Chem       Date:  2010-08-20       Impact factor: 5.157

2.  Calpain is required for normal osteoclast function and is down-regulated by calcitonin.

Authors:  Marilena Marzia; Riccardo Chiusaroli; Lynn Neff; Na-Young Kim; Athar H Chishti; Roland Baron; William C Horne
Journal:  J Biol Chem       Date:  2006-02-03       Impact factor: 5.157

3.  Interferon-inducible protein 9 (CXCL11)-induced cell motility in keratinocytes requires calcium flux-dependent activation of mu-calpain.

Authors:  Latha Satish; Harry C Blair; Angela Glading; Alan Wells
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

4.  Non-steroidal anti-inflammatory drugs inhibit calpain activity and membrane localization of calpain 2 protease.

Authors:  Kristopher Silver; Ludovic Leloup; Lisa C Freeman; Alan Wells; James D Lillich
Journal:  Int J Biochem Cell Biol       Date:  2010-09-18       Impact factor: 5.085

Review 5.  The calpain system and cancer.

Authors:  Sarah J Storr; Neil O Carragher; Margaret C Frame; Tim Parr; Stewart G Martin
Journal:  Nat Rev Cancer       Date:  2011-05       Impact factor: 60.716

6.  Effect of Melatonin on Glutamate: BDNF Signaling in the Cerebral Cortex of Polychlorinated Biphenyls (PCBs)-Exposed Adult Male Rats.

Authors:  S Bavithra; E Sugantha Priya; K Selvakumar; G Krishnamoorthy; J Arunakaran
Journal:  Neurochem Res       Date:  2015-07-30       Impact factor: 3.996

7.  Epidermal growth factor activates m-calpain (calpain II), at least in part, by extracellular signal-regulated kinase-mediated phosphorylation.

Authors:  A Glading; R J Bodnar; I J Reynolds; H Shiraha; L Satish; D A Potter; H C Blair; A Wells
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

Review 8.  Calpain dysregulation in Alzheimer's disease.

Authors:  Adriana Ferreira
Journal:  ISRN Biochem       Date:  2012-10-16

Review 9.  The calpain system as a potential target for pelvic muscle reinforcement.

Authors:  Mariusz Blewniewski; Ewa Forma; Waldemar Różański; Magdalena Bryś
Journal:  Cent European J Urol       Date:  2011-09-06

10.  Platelets of mice heterozygous for neurobeachin, a candidate gene for autism spectrum disorder, display protein changes related to aberrant protein kinase A activity.

Authors:  Kim Nuytens; Krizia Tuand; Michela Di Michele; Kurt Boonen; Etienne Waelkens; Kathleen Freson; John Wm Creemers
Journal:  Mol Autism       Date:  2013-11-04       Impact factor: 7.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.